Anne F. Schott, MD
Advertisement
Articles by Anne F. Schott, MD
24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han
This second edition of the text edited by Bland and Copeland represents a comprehensive reference that reviews the history, pathobiology, and current clinical management of diseases of the breast. Much more than a book about breast
Advertisement
Latest Updated Articles
- The Breast: Comprehensive Management of Benign and Malignant Diseases, Second Edition
Published: February 1st 2001 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer
2
FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM
3
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
4
Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer
5
